Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial

作者：Sharana Mahomed, Nigel Garrett, Edmund V. Capparelli, Farzana Osman, Nonhlanhla N. Mkhize, Ishana Harkoo, Tanuja N. Gengiah, Leila E. Mansoor, Cheryl Baxter, Derseree Archary, Nonhlanhla Yende‐Zuma, Natasha Samsunder, Kevin Carlton, Sandeep Narpala, Adrian B. McDermott, Nicole A. Doria‐Rose, Penny L. Moore, Lynn Morris, Quarraisha Abdool Karim, John R. Mascola, Salim S. Abdool Karim · 发表于：The Lancet HIV · 年份：2023 · DOI：10.1016/s2352-3018(23)00003-6 · 被引用次数：42 · 研究领域：HIV Research and Treatment、HIV/AIDS Research and Interventions、HIV/AIDS drug development and treatment